Genome Sequencing (DNA) Test
Test specific gens to determine if you have genetic traits linked to vairous diseases. Based on the results of the analysis we can develop a personalised program that significantly reduces your personal disease risk and helps you stay healthy.
Comprehensive DNA Testing: Transforming Genetic Insights into Proactive Health Strategies
In the evolving landscape of personalized medicine, DNA testing has emerged as a pivotal tool, offering profound insights into an individual's genetic predispositions. At Swissmed Health, we transcend traditional genetic assessments by providing actionable strategies that integrate biomarker analysis and personalized treatment plans. Our objective is to empower individuals to proactively manage their health, preventing genetic predispositions from manifesting into actual conditions.
Understanding Genetic Predispositions
Genetic predispositions refer to the increased likelihood of developing certain diseases based on one's genetic makeup. While possessing a genetic variant associated with a disease does not guarantee its onset, it does indicate a higher risk. For instance, specific mutations in the BRCA1 and BRCA2 genes are linked to a heightened risk of breast and ovarian cancers. Recognizing these predispositions enables individuals to make informed decisions about their health.
Our Distinctive Approach: From Genetic Insights to Actionable Health Plans
At Swissmed Health, we believe that knowledge of genetic risks should be the foundation for proactive health management. Our comprehensive DNA testing services are designed to provide:
In-Depth Genetic Analysis
Biomarker Assessment
Personalized Treatment Plans
The Role of Biomarkers in Personalized Medicine
Biomarkers are measurable indicators of biological states or conditions. In the context of genetic testing, they provide real-time data on how genetic predispositions may be influencing physiological processes. For example, elevated levels of certain proteins might indicate inflammation, which could be linked to genetic variants associated with cancer. By monitoring these biomarkers, we can tailor interventions to address specific health concerns effectively.
Scientific Foundations and Research
Our approach is grounded in robust scientific research. Studies have demonstrated the efficacy of integrating genetic testing with biomarker analysis to develop personalized health interventions. For instance, research published in the *Journal of Personalized Medicine* highlights how combining genetic data with biomarker profiles can enhance the prediction and prevention of complex diseases.
Furthermore, a study in the *Journal of Translational Medicine* emphasizes the importance of actionable recommendations following genetic testing. The research indicates that personalized interventions based on genetic and biomarker information can lead to significant improvements in health outcomes.
Case Study: Proactive Management of Cancer Risk
Consider a patient with a genetic predisposition to breast cancer, identified through mutations in the BRCA1 or BRCA2 genes. Traditional approaches might include periodic screenings. However, at Swissmed Health, we go beyond by assessing biomarkers such as CA 15-3 and circulating tumor DNA (ctDNA), which can indicate early signs of tumor activity. With this information, we develop a proactive plan that includes tailored nutritional strategies to reduce estrogen levels, targeted physical activity to strengthen the immune system, and the use of preventive therapeutics to lower the risk of cancer development. This comprehensive approach empowers patients to take control of their health, potentially delaying or even preventing the onset of cancer. Comprehensive DNA testing, when combined with biomarker analysis and personalized treatment plans, offers a powerful approach to preventive healthcare. By understanding genetic predispositions and taking proactive steps, individuals can significantly reduce their risk of developing certain conditions. At Swissmed Health, we are committed to providing these insights and supporting our clients in their pursuit of optimal health.
References
1. "Personalized medicine using DNA biomarkers: a review." *Journal of Human Genetics*, 2012. (https://link.springer.com/article/10.1007/s00439-012-1188-9)
2. "Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Drugs." *Genes*, 2024. (https://www.mdpi.com/2073-4425/15/4/468)
Molecular Diagnostic Tailoring Personalized Cancer Therapy: An Oncologist’s View
Medical oncology is rapidly evolving with the implementation of personalized, targeted therapies. Advances in molecular diagnostics and the biologic understanding of cancer pathophysiology led to the identification of specific genetic alterations as drivers of cancer progression. Further, improvements in drug development enable the direct interference with these pathways, which allow tailoring personalized treatments based on a distinct molecular characterization of tumors. Thereby, we are currently experiencing a paradigm-shift in the treatment of cancers towards cancer-type agnostic, molecularly targeted, personalized therapies. However, this concept has several important hurdles and limitations to overcome to ultimately increase the proportion of patients benefitting from the precision oncology approach. These include the assessment of clinical relevancy of identified alterations, capturing and interpreting levels of heterogeneity based on intra-tumoral or time-dependent molecular evolution, and challenges in the practical implementation of precision oncology in routine clinical care. In the present review, we summarize the current state of cancer-agnostic precision oncology, discuss the concept of molecular tumor boards, and consider current limitations of personalized cancer therapy. Further, we provide an outlook towards potential future developments including the implementation of functionality assessments of identified genetic alterations and the broader use of liquid biopsies in order to obtain more comprehensive and longitudinal genetic information that might guide personalized cancer therapy in the future.